|
Resolution: standard / high Figure 5.
The cost-effectiveness acceptability curves showing the probabilities of net benefits
achieved by the Gefitinib strategy compared to the Control strategy at different WTP
thresholds in advanced NSCLC patients.
Zhu et al. BMC Cancer 2013 13:39 doi:10.1186/1471-2407-13-39 |
